Not long ago, I participated in the fourth negotiation on the adjustment of the national medical insurance drug catalog. So far, although there have been over 100 negotiations, the tension still exists when it comes to the significant importance of medical insurance drugs. The seemingly confrontational scenes of striving for win-win situations are both emotional and touching. The negotiation of adjusting the national medical insurance drug catalog is not only related to the large pool of medical insurance funds, but also to the people's financial situation. Different from commercial negotiations, ensuring standardization is the primary principle in the negotiation of adjusting the national medical insurance drug catalog. The negotiation expert group must strictly follow the rules to negotiate with representatives of pharmaceutical companies, ensuring that all participating pharmaceutical companies can receive fair and equal rights protection. Adhering to a position is a basic requirement. From the perspective of their own development, pharmaceutical companies can only lower prices within a limited range. Negotiators need to understand and learn to think from different perspectives. They cannot demand unrealistic reductions based on personal wishes, nor can they ignore the negotiation responsibility of striving for better prices for insured individuals. In recent years, negotiations on adjusting the national medical insurance drug catalog have been referred to by many as "soul negotiations". The negotiation bottom price is based on the expected acceptable payment standards of medical insurance and is calculated scientifically in the early stage. Negotiators are responsible for using negotiation rules to strive for greater benefits for insured individuals, provided that they are acceptable to pharmaceutical companies. From this point of view, every negotiation expert will spare no effort in bargaining, striving for every penny. It is precisely because it carries the expectations of countless insured individuals that negotiation experts can truly express their emotions and bring their own aura. The pursuit of negotiation experts is to have equal and full communication with pharmaceutical representatives, and to strive for the best price that pharmaceutical companies can accept for patients. But at the negotiation table, sticking together is the norm. In a negotiation on rare disease medication, although the company's quotation fell within the range of 115% of the base price, progress has been difficult in the negotiation process. The enterprise representative walked out of the negotiation site several times to seek instructions, and nervousness and anxiety filled the entire room. In fact, we sitting on the other side of the negotiation table are equally nervous. On the one hand, we hope to lower the price to the most reasonable level, and on the other hand, we are also concerned that negotiations may fail and the medication burden on rare disease patients may not be reduced. The final negotiation was successful. "Congratulations!" When I said this to the company representative, everyone couldn't help but applaud. Establishing a medical insurance access and negotiation renewal mechanism with new drugs as the main body is essential for the adjustment of the national medical insurance drug catalog. The research and development cost of innovative drugs is high, and it is difficult to strive for price reductions, but many companies have also taken the initiative. In a negotiation, the chairman of a pharmaceutical company, who is a scientist, took the initiative to propose a price reduction to allow more patients to use their own drugs that have been developed for many years. The finance director next to him was so anxious that he stomped his feet. It is reported that the expenditure of medical insurance on new drugs increased from 5.949 billion yuan in 2019 to 48.189 billion yuan in 2022, an increase of 7.1 times. The waiting time for new drugs to be included in the medical insurance catalog has been shortened from an average of nearly 5 years in the past to less than 2 years. Some new drugs are included in the medical insurance catalog after only half a year of being launched. It has been proven that seeking the "greatest common divisor" between price and innovation is the key to achieving a mutually beneficial "two-way journey". Cracking down on the problem of expensive medical treatment for the masses has always been an important goal of deepening medical reform. In recent years, the medical insurance department has always adhered to the principle of benefiting the people,